Caricamento...
Combined vaccine + axitinib therapy yields superior anti-tumor efficacy in a murine melanoma model
Axitinib, a tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors has demonstrated modest efficacy when applied as a single agent in the setting of advanced-stage melanoma. Based on the reported ability of axitinib to “normalize” the tumor vasculature, we hypothesize that c...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2012
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3340498/ https://ncbi.nlm.nih.gov/pubmed/22504156 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0b013e3283538293 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|